> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# CONMED Narrows Its 2026 Sales Range, Raises Profit Forecast As Margin Widens To 56.4%
- URL: https://www.bullished.co/conmed-narrows-its-2026-sales-range-raises-profit-forecast-as-margin-widens-to-56-4-e7b0f693/
- Published: 2026-10-28T20:28:48.000Z
- Updated: 2026-10-28T20:28:48.000Z
- Description: The surgical-device maker's third-quarter sales slipped 0.7% as it exited GI products, while gross margin climbed from 49.2% a year earlier.
- Author: Matteo Parrino
- Tags: Earnings, CNMD, Industry: Healthcare

CONMED, the medical technology company that makes devices for surgical procedures, said [third-quarter sales](https://www.sec.gov/Archives/edgar/data/0000816956/000081695626000110/cnmdearningsrelease9302026.htm?ref=bullished.co) slipped 0.7% to $335.6 million as it exited some gastrointestinal product lines. It narrowed its 2026 sales range and lifted the low and high ends of its adjusted profit forecast, the company said Wednesday in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filing.

## Exits Mask Underlying Growth

Sales fell 0.8% in constant currency. Excluding the GI product lines the company previously announced it was exiting, net sales rose 6.7% on an organic constant-currency basis.

Domestic sales fell 11.0% as reported but rose 0.8% organically. International sales rose 13.1% as reported and 13.8% on an organic constant-currency basis.

CEO Patrick J. Beyer said organic growth came from both product lines, powered by AirSeal, Buffalo Filter and BioBrace. Orthopedic surgery sales rose 7.7% to $148.8 million, while general surgery fell 6.5% to $186.7 million.

## Margin Jumps From A Weak Year-Ago Quarter

Gross profit was 56.4% of sales, up from 49.2% a year earlier, when $19.7 million of product rationalization costs, including inventory and patent write-offs, hit results. Operating income rose to $37.1 million from $11.9 million.

Diluted earnings per share under standard accounting were $0.66, up 613.7%. Adjusted earnings per share were $1.04, down 3.2% from $1.08\. Beyer said adjusted EPS exceeded the company's expectations.

## Guidance: Tighter Sales, Higher Profit

CONMED now expects 2026 net sales of $1,360 million to $1,366 million, against a prior range of $1,358 million to $1,373 million set July 29\. Adjusted EPS is forecast at $4.54 to $4.61, versus $4.48 to $4.60 before.

Organic constant-currency sales growth is guided at 5.0% to 5.5%, with the top end trimmed from 6.0%.

CONMED, based in Largo, Florida, sells orthopedic and general surgery products in over 100 countries. Management holds a conference call at 4:30 p.m. ET Wednesday.

Management discusses the quarter and updated outlook on its 4:30 p.m. ET call Wednesday.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — CONMED Corp (CNMD)](https://www.sec.gov/Archives/edgar/data/0000816956/000081695626000110/cnmd-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit cnmdearningsrelease9302026.htm — CONMED Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000816956/000081695626000110/cnmdearningsrelease9302026.htm?ref=bullished.co) — SEC EDGAR